Hemogenyx Pharmaceuticals Plc
HEMO.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | £314 | £318 | £322 | £326 |
| Gross Profit | -£314 | -£318 | -£643 | -£326 |
| % Margin | – | – | – | – |
| R&D Expenses | £0 | £237 | £0 | £91 |
| G&A Expenses | £2,264 | £2,368 | £2 | £1,924 |
| SG&A Expenses | £2,264 | £2,368 | £2,369 | £1,924 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | £0 | -£237 | £0 | -£91 |
| Operating Expenses | £2,264 | £2,368 | £2,369 | £1,924 |
| Operating Income | -£2,578 | -£2,686 | -£3 | -£2,250 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -£2,428 | -£124 | -£0 | -£123 |
| Pre-Tax Income | -£5,006 | -£2,810 | -£3 | -£2,373 |
| Tax Expense | £0 | £0 | £0 | £0 |
| Net Income | -£5,004 | -£2,806 | -£3 | -£2,370 |
| % Margin | – | – | – | – |
| EPS | -1.42 | -0.8 | -0.001 | -0.81 |
| % Growth | -77.5% | -88,788.9% | 99.9% | – |
| EPS Diluted | -1.42 | -0.8 | -0.001 | -0.81 |
| Weighted Avg Shares Out | 3,535 | 3,505 | 3,067 | 2,939 |
| Weighted Avg Shares Out Dil | 3,536 | 3,505 | 3,067 | 2,939 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £6 | £35 | £31 |
| Interest Expense | £120 | £130 | £284 | £154 |
| Depreciation & Amortization | £314 | £318 | £643 | £326 |
| EBITDA | -£4,573 | -£2,363 | -£4,704 | -£1,893 |
| % Margin | – | – | – | – |